Professional Documents
Culture Documents
Original Research
ASTHMA
Results
Description of Study Cohort
A total of 723 children were enrolled in the
study, of whom 139 were allowed to reenroll and be
CHEST / 145 / 4 / APRIL 2014
773
1 Point
34
30
26
23
. 95 on room air
Normal breathing or
end-expiratory wheezing
None or intercostal
Speaks in sentences or coos
and babbles
2 Points
35-39
31-35
27-30
24-27
90-95 on room air
Expiratory wheezing
Intercostal and substernal
Speaks in partial sentences
or utters short cries
3 Points
40
36
31
28
, 90 on room air or supplemental oxygen
Inspiratory and expiratory wheezing,
diminished breath sounds, or both
Intercostal, substernal, and supraclavicular
Speaks in single words or short phrases
or grunts
Figure 1. Study enrollment chart. Seventy-six subjects were excluded because they declined to participate
from the beginning of the study, and 110 declined after reading the consent form, which was fully explained.
774
Original Research
Table 2Comparison of Baseline Demographics and Clinical Characteristics of Budesonide vs Placebo Groups
Baseline Characteristics
Age, y
2-6
7-12
Female sex
Family history of asthma
Parental (mother, father, or both)
Siblings (one or more)
Smokers at home
Trigger, upper respiratory infection
Children with past medical history of:
Admission to ward or PICU (lifetime)
ED visits (in last year)
None
b2-Agonist inhalations (or equivalent nebulizers) during
the 6 h prior to presentation, No.
5
3-4
1-2
None
Inhaled corticosteroid prophylaxis
Montelukast prophylaxis
Budesonide (458)
No. (%)
Placebo (448)
No. (%)
P Value
305 (66.59)
153 (33.41)
156 (34.06)
310 (69.20)
138 (30.80)
161 (35.94)
.40
.55
208 (45.41)
328 (71.62)
83 (18.12)
385 (84.06)
199 (44.42)
301 (67.15)
86 (19.20)
394 (87.95)
.76
.15
.68
.09
196 (42.79)
243 (53.06)
19 (4.15)
208 (46.43)
219 (48.88)
21 (4.69)
.45
32 (6.99)
98 (21.40)
161 (35.15)
167 (36.46)
120 (26.20)
31 (6.77)
22 (4.91)
87 (19.42)
155 (34.60)
184 (41.07)
117 (26.12)
33 (7.37)
.34
.98
.73
775
References
1. Eder W, Ege MJ, von Mutius E. The asthma epidemic.
N Engl J Med. 2006;355(21):2226-2235.
2. Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology,
etiology and risk factors. CMAJ. 2009;181(9):E181-E190.
3. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality
in Europe (AIRE) study. Eur Respir J. 2000;16(5):802-807.
4. Tsai CL, Lee WY, Hanania NA, Camargo CA Jr. Age-related
differences in clinical outcomes for acute asthma in the United
States, 2006-2008. J Allergy Clin Immunol. 2012;129(5):
1252-1258.
5. Pollack CV Jr, Pollack ES, Baren JM, et al; Multicenter
Airway Research Collaboration Investigators. A prospective
multicenter study of patient factors associated with hospital
admission from the emergency department among children
with acute asthma. Arch Pediatr Adolesc Med. 2002;156(9):
934-940.
6. Global strategy for asthma management and prevention.
Global Initiative for Asthma website. http://www.ginasthma.org/
GINA-Report,-Global-Strategy-for-Asthma-Management-andPrevention. Updated December 2012. Accessed June 10, 2013.
7. Expert panel report 3: guidelines for the diagnosis and management of asthma 2007. National Heart, Lung and Blood
Institute website. https://www.nhlbi.nih.gov/guidelines/asthma/
asthgdln.pdf. Accessed June 10, 2013.
8. Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus
intermittent beta-agonists in the treatment of acute asthma.
Cochrane Database Syst Rev. 2003;(4):CD001115.
9. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the
treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005;60(9):740-746.
CHEST / 145 / 4 / APRIL 2014
777
778
21. Schuh S, Dick PT, Stephens D, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild
to moderate acute asthma. Pediatrics. 2006;118(2):644-650.
22. Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled
fluticasone and oral prednisone for children with severe acute
asthma. N Engl J Med. 2000;343(10):689-694.
23. Rodrigo GJ, Rodrigo C. Triple inhaled drug protocol for
the treatment of acute severe asthma. Chest. 2003;123(6):
1908-1915.
24. Manser R, Reid D, Abramson M. Corticosteroids for acute
severe asthma in hospitalised patients. Cochrane Database
Syst Rev. 2001;(1):CD001740.
25. Belda J, Margarit G, Martnez C, et al. Anti-inflammatory effects
of high-dose inhaled fluticasone versus oral prednisone in
asthma exacerbations. Eur Respir J. 2007;30(6):1143-1149.
26. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI,
OConnor BJ. Rapid effect of inhaled fluticasone propionate
on airway responsiveness to adenosine 59-monophosphate in
mild asthma. J Allergy Clin Immunol. 2002;110(4):603-606.
27. Horvath G, Wanner A. Inhaled corticosteroids: effects on the
airway vasculature in bronchial asthma. Eur Respir J. 2006;
27(1):172-187.
28. Alangari AA. Genomic and non-genomic actions of glucocorticoids in asthma. Ann Thorac Med. 2010;5(3):133-139.
29. Bisgaard H, Nikander K, Munch E. Comparative study of
budesonide as a nebulized suspension vs pressurized metereddose inhaler in adult asthmatics. Respir Med. 1998;92(1):44-49.
30. Kelly HW. Establishing a therapeutic index for the inhaled
corticosteroids: part I. Pharmacokinetic/pharmacodynamic
comparison of the inhaled corticosteroids. J Allergy Clin
Immunol. 1998;102(4 pt 2):S36-S51.
31. Sims MW. Aerosol therapy for obstructive lung diseases:
device selection and practice management issues. Chest. 2011;
140(3):781-788.
32. Ducharme FM, Davis GM. Measurement of respiratory resistance in the emergency department: feasibility in young children with acute asthma. Chest. 1997;111(6):1519-1525.
Original Research